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ABSTRACT 
 
 
 
Janetsian, Sarine Sona. M.S., Purdue University, December 2013. Temporally 
Distinct Impairments in Cognitive Function Following a Sensitizing Regimen of 
Methamphetamine. Major Professor: Christopher C. Lapish.  
 
 
          Methamphetamine (MA) is a widely abused psychostimulant that has been 
shown to evoke an array of neurobiological abnormalities and cognitive deficits in 
humans and in rodent models (Marshall & O'Dell, 2012). Alterations in cognitive 
function after repeated drug use may lead to impaired decision-making, a lack of 
behavioral control, and ultimately the inability to abstain from drug use. Human 
studies have shown that alterations in neurobiology resulting from prolonged MA 
use may lead to a number of cognitive deficits, including impairments in 
executive function, learning, memory, and impulsivity. These impairments, 
specifically those that engage the prefrontal cortex (PFC) or hippocampus (HC), 
may persist or recover based on the duration of abstinence. In rodents, repeated 
intermittent injections of MA yield protracted changes in neurobiology and 
behavior, which have been shown to effectively model a number of the biological 
and cognitive abnormalities observed in addiction. In order to assess the 
temporal evolution of impaired cognitive function throughout abstinence, 
sensitization was first induced in rats (7 x 5.0 mg/kg MA over 14 days). MA-
treated rats initially exhibited a robust increase in locomotion that 
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transitioned to stereotypy as the induction phase progressed. Then, the effects of 
MA sensitization on social interaction (SI), temporal order recognition (TOR) and 
novel object recognition (NOR) was assessed at one-day and 30-days post 
induction. No differences were observed in SI in either group or after a single 
injection of MA. However, an acute injection of 5.0 mg/kg of MA 30-minutes prior 
to testing dramatically reduced SI time. Impairments in TOR and NOR were 
observed in MA-treated rats after one day of abstinence, and impairments in 
TOR, but not NOR, were observed on day 30 of abstinence. No differences in 
TOR and NOR after a single injection of MA or saline were observed. These data 
establish that after 30 days of abstinence from a sensitizing regimen of MA, the 
ability to recall the temporal sequence that two stimuli were encountered was 
impaired and that was not attributable to impaired novelty detection. These data 
also suggest that at least some of the neurocognitive abnormalities caused by 
chronic MA administration may normalize after prolonged abstinence, since the 
ability to detect novelty recovered after 30 days of abstinence. These data 
provide compelling support that, since MA-sensitization caused temporal deficits 
in memory, PFC and HC function may be differentially impaired throughout the 
time course of abstinence. 
 
 
 
 
 
 
 
   
 
1 
INTRODUCTION 
 
 
 
Prevalence 
 
Methamphetamine (MA) is an addictive Schedule-II psychostimulant that 
is widely abused around the world. With the number of abusers on the rise, the 
United Nations Office on Drugs and Crime (2011) reports that MA and other 
types of amphetamines are the second most widely used illicit drugs in the world, 
even exceeding cocaine and opiates, with an estimate of 13.7 to 56.4 million 
users worldwide.  The National Survey on Drug Use and Health (2010) reports 
that in the United States, 353,000 people aged 12 and older have used MA and 
105,000 people aged 12 and older initiated MA use for the first time in 2010. In 
addition, 2.5% of 10th graders have used MA at least once in their lifetime (United 
Nations Office on Drugs and Crime, 2011). It is even popular among adults; with 
11% of 18-year-old high school graduates and 52% of 50-year-old individuals 
having reported use of amphetamine at least once (Johnson et al., 2009). In fact, 
the percentage of individuals being admitted to a U.S. state licensed or certified 
substance abuse facility for MA treatment has increased from 1% in 1992 to 5% 
in 2010 (TEDS, 2011).  
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The high potential for continued MA use and abuse may be due to the 
ability for MA to cause impairments in cognition and decision making, in addition 
to the hedonic properties of the drug and the inexpensive nature to manufacture 
this substance using over-the-counter ingredients (Nordahl et al., 2003). 
Manufacturing MA has become an epidemic, with 10,287 MA lab incidents in 
2011 alone (US DEA, 2011). Also, its production has increased and prices have 
decreased from 2008 (U.S. Department of Justice National Drug Intelligence 
Center, 2011), making it more available and affordable to the population. 
Increased production not only leads to an increase in the number of the drug 
users, but the illicit trade of the drug poses a larger threat to security, society, 
and health (UNODC, 2011). According to the National Institute on Drug Abuse 
(2010), MA not only causes cognitive deficits and neurophysiological changes, 
but it can cause physical changes including extreme weight loss and severe 
dental problems, as well as anxiety, confusion, insomnia, paranoia, 
hallucinations, violent behavior and some changes in mood. Given the 
substantial number of users and manufacturers, MA continues to be a major 
public health concern due to its highly addictive and potentially neurotoxic nature 
that can cause cognitive and neurological abnormalities arising from acute or 
repeated use. Elucidating the neural substrates of MA-induced cognitive 
impairments will allow for the evaluation of recovery prognosis as well as 
potential pharmacological treatments that may assist in the process.   
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Mechanism of Action 
 
 The mechanisms of action of MA have been extensively studied and are 
critical to inform our understanding of the persistent changes in neurobiology, 
neurochemistry and cognitive impairments brought upon by repeated use of the 
drug. MA acts primarily as an indirect dopamine (DA) agonist (Bannon, 1987). 
MA is highly lipophilic and crosses the blood brain barrier (BBB) faster than other 
psychostimulants (Cho, 1990). It enters the DA neuron via the DA transporter 
(DAT) and by passive diffusion (Kajitani et al., 1989). After entering the synapse, 
it increases extracellular DA, serotonin (5-HT), and norepinephrine (NE) levels in 
several different ways. Two competing models exist with opposing views on how 
MA elicits increases in extracellular monoamine levels.  
 (1) In the exchange diffusion model (Fischer & Cho, 1979), MA acts 
primarily on plasma membrane monoamine uptake transporters. Specifically, 
extracellular MA binds to DAT where it is substituted or exchanged with 
intracellular DA and is transported via DAT into the cell. However, a 
concentration-dependent mechanism of DA release has also been suggested 
(Liang & Rutledge, 1982). At lower concentrations of extracellular MA, MA binds 
to DAT and is exchanged for cytosolic DA, which is transported along its 
concentration gradient via accelerated exchange diffusion, causing increases in 
extracellular DA concentration. At higher concentrations of extracellular MA, MA 
diffuses through the plasma membrane because it is highly lipophilic and 
accumulates inside the presynaptic terminal, where it releases DA from binding 
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to intracellular binding sites, including monoamine oxidase (MAO) or other 
transporters, causing DA to exit the cell along its concentration gradient from the 
intracellular field to the extracellular field via reversal of normal DAT, 5-HT 
transporter (SERT) and in higher doses, norepinephrine transporter (NET) 
function.  
 (2) The weak base model states that the primary site of action of 
amphetamines is at secretory vesicles (Sulzer et al., 1990 & 1992). Based on this 
model, accumulation of monoamines in synaptic vesicles found in presynaptic 
terminals depends on the interior-acidic pH gradient. After MA enters neurons by 
lipophilic diffusion and by the DAT, it penetrates the vesicles filled with 
monoamines via the vesicular monoamine transporter (VMAT-2) and reduces the 
intracellular pH gradient to more basic. Since psychostimulants are weak bases, 
it increases the pH of the vesicles to 5.6 from a normal of 5.5 and also leads to a 
pH increase in the external medium to 7.4 from a normal 7.25. MA accumulates 
in the vesicle and displaces monoamines from the vesicles via the VMAT-2. 
Since  the  vesicle’s  interior-acidic pH gradient is reduced, the buffering capacity of 
the vesicle is exceeded and the driving force for monoamine uptake back into the 
vesicle is suppressed, causing monoamine release and build-up in the cytosol, 
which is then released into the extracellular field via reverse transport of DAT.    
 Other mechanisms include (3) blocking reuptake of DA, NE, and at higher 
levels, 5-HT (Kokoshka et al., 1998), also resulting in increases in monoamine 
levels in the synapse. Lastly, (4) MA can bind to MAO in DA neurons and 
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prevents the degradation of DA, which leaves free DA in the presynaptic 
terminal, which can then be taken into extracellular fluid by reverse transport.  
 Although there is a compelling support for the two competing hypotheses 
and mechanisms of action for MA, these mechanisms are not mutually exclusive. 
For example, the exchange diffusion model and the weak base model both agree 
that MA is transported into the cell via DAT and by passive diffusion. However, it 
is at the primary site of action where there is disagreement between the two 
models. The exchange diffusion model proposes that the primary site of action 
for DA release is at the transporter level, whereas the weak base model suggests 
that it is at the secretory vesicles. However, it is possible that the release of DA 
from the secretory vesicles (weak base model) is necessary for DA to be 
released into the cytosol before DA binds to DAT (exchange diffusion model). 
Furthermore, both models are in agreement when they propose that MA is 
transported via passive diffusion and DAT, but after MA enters the cell and 
penetrates DA-filled vesicles that then release DA is when DA accumulates in the 
cytosol. After accumulation of DA, additional extracellular MA binds to DAT and 
DA is then substituted for MA and released into the extracellular field. In support 
of this speculation, Jones et al. (1998) reports that reversal of DAT and release 
of vesicular DA are both necessary for extracellular release of DA, although 
depletion of DA in the vesicle is the rate-limiting step in the extent to which DA is 
released. This suggests that both models are critical for the release of 
extracellular DA, although the weak base model may be fundamental in this 
process.  
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 Although these models are crucial to our understanding of the immediate 
mechanisms of action of MA, it is important to consider neurotoxicity caused by 
heavy use, which is exemplified by increases in markers of oxidative stress and 
apoptosis in animal models (Yamamoto & Zhu, 1998; Cubells & Sulzer, 1994; 
Jayanthi et al., 2004; Nakato et al., 2011). MA-induced neurotoxicity is observed 
in animal models of binging, which consists of multiple injections of MA in a 
single day. MA can produce free radicals such as reactive oxygen species (ROS) 
and nitric oxide (NO), which can both result in neuronal cell death. When MA 
enters the cell, it enters vesicles (weak base model) and mitochondria. Then, DA 
and 5-HT are released from vesicles and are oxidized via MAO. Oxidative stress 
causes mitochondria permeability transition (MPT) pores to open, which results 
in an increase in calcium and an increase in glutamate release. An increase in 
calcium can either cause low ROS or high ROS, which results in apoptosis or 
necrosis, respectively (Davidson et al., 2001). An increase in glutamate can 
cause excitotoxicity, which can also result in neuronal cell death (Stout et al., 
1998).  
 In conclusion, the mechanisms of action of MA described above not only 
pertain to animal models of MA use, but also occur in human MA users. 
Additionally, it is thought that acute overdose of MA in humans may result in 
neurotoxicity because it parallels animal binge models of MA administration 
(Davidson et al., 2001).  
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Human Studies  
 Previous human and rodent literature has heavily concentrated on the 
neurobiological and neurochemical effects induced by MA use. In humans, most 
of the literature encompasses techniques including Magnetic Resonance Imaging 
(MRI), functional MRI (fMRI), Magnetic Resonance Spectroscopy (MRS), and 
Positron Emission Tomography (PET) to observe tissue density, 
neurotransmission, neuronal deterioration, etc. (Salo et al., 2011). Cognitive 
function after MA use is also assessed using various behavioral assays including 
the Wisconsin Card Sort Test (WCST), Attentional Network Task (ANT), Stroop 
Task, etc.  
  As mentioned above, individuals who chronically abuse MA exhibit a wide 
array of cognitive impairments (Marshall  &  O’Dell,  2012). These include impaired 
time perception (Wittmann et al., 2007), impaired decision-making (Paulus et al., 
2003), poor recall memory (Simon et al., 2000), increased impulsivity (Hoffman et 
al., 2006), and deficits in attention (Salo et al., 2009). Impairments in cognitive 
function are paralleled by a number of persistent changes in neurobiology. In 
human immunoreactivity studies, direct effects of MA are observed on glutamate 
(GLUT), DA, and 5-HT systems which point to a broad and complex array of 
neuroadaptive changes in the brain, including reductions in DA content and in 
DAT density (Wilson et al., 1996), decreases in 5-HT and tyrosine hydroxylase 
(TH) levels (Kish et al., 2009), and reductions in SERT density (Sekine et al., 
2006).  
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Neurobiological Effects After Abstinence 
 
 The long-term behavioral, neurobiological and neurochemical effects of 
MA abuse are not static, but rather appear to change with both the duration and 
the period of abstinence following MA use. For example, individuals abstinent for 
more than six months show increased gray matter density in the right medial 
prefrontal cortex (mPFC) compared to individuals abstinent for shorter periods 
(Kim et al., 2006).  Alterations in this brain region may be particularly important 
as it plays a central role in executive function (Habets et al., 2008). These studies 
suggest that there is partial recovery of grey matter density, which consists of 
neuronal cell bodies, glial cells, and capillaries, after prolonged abstinence. This 
suggests that longer periods of abstinence from MA can potentially normalize 
brain function. Additionally, reductions in neurotransmitter transporter expression 
associated with long-term MA use seem to recover with extended abstinence. 
Volkow et al. (2001) have shown that DAT expression is significantly increased in 
the caudate and putamen in individuals abstinent for nine months when 
compared to individuals abstinent for less than six months, suggesting 
remediation of this crucial neurobiological factor that controls the bioavailability of 
DA in the brain after prolonged abstinence. However, in the same study, motor 
and memory function did not seem to recover in these individuals to the same 
extent as did DAT levels, suggesting that recovery of DAT alone is not sufficient 
for full normalization of motor and memory function.  
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Neurochemical Effects After Abstinence 
 
 Neurochemical differences have also been observed following abstinence 
from MA. GLUT and glutamine levels are reduced in the frontal cortex in 
individuals abstinent for less than one month, with less reduction in individuals 
abstinent for longer periods (Ernst & Chang, 2009). In the same study, 
individuals with symptoms of craving had lower levels of GLUT and glutamine 
compared to levels of those who had no cravings. Therefore, since reductions in 
GLUT and glutamine are suspected to play a role in craving in rodents using self-
administration models (Hasler et. al, 2007; Baker et al. 2003), the 
aforementioned study suggests that prolonged abstinence can potentially 
minimize or reduce the propensity to crave the drug and possibly relapse. Taken 
together, these studies show that although MA causes alterations in neurobiology 
and neurochemistry after repeated use, there is potential for an individual to 
exhibit increases in cell density and DAT availability, which play a role in crucial 
brain functions, after prolonged periods of abstinence. Additionally, since altered 
brain function such as a decrease in GLUT and glutamine levels is associated 
with craving and cognitive functions (Kim et al., 2006), partial or full recovery of 
these neuronal alterations can possibly mitigate the propensity to relapse or the 
cognitive deficits otherwise observed in MA-addicted individuals.   
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Cognitive Effects After Abstinence 
  
 Similar to findings of the neurobiological effects of MA after prolonged 
abstinence, a number of cognitive abnormalities persist following chronic MA 
use; however, some are ameliorated with time. Two studies by Salo et al. (2009 
& 2011) examined alerting, orienting, and executive function in a task called the 
Attentional Network Task (ANT). The ANT identifies specific deficits, such as 
alerting, orienting, and executive function by presenting participants with a target 
item (>) that is surrounded by congruent (>>>>>), incongruent (<<><<), or 
neutral stimuli (-->--). The participants have to identify the target stimulus and 
these tasks measure executive control and attention shifting. The authors found 
differences in short-term (less than one year) vs. long-term (more than one year) 
abstinent individuals in the ability to ignore the distracting stimuli associated 
within the ANT, suggesting that individuals abstinent from MA for a shorter period 
of time had more profound deficits in shifting attention compared to MA users 
abstinent for longer periods. Other studies also support the hypothesis of partial 
or full recovery of cognitive abilities. Amongst these is a study by Kim et al. 
(2006) that examined a positive correlation between scores on the Wisconsin 
Card  Sort  Test   (WCST),  a   test   that  examines   the  participant’s  ability   to  display  
behavioral flexibility when asked to shift attention to different stimuli, and grey 
matter density, known to be associated with executive function. Also, a study by 
Chang et al. (2002) shows that abstinent MA users had slower reaction times on 
tasks that require working memory, such as the one-back cued response and 
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three sequential number task, when compared to control subjects. These studies 
support the hypothesis that some aspects of cognition can recover after certain 
periods of abstinence, with the most cognitive recovery occurring after prolonged 
periods. Lastly, it is possible that these improvements may be associated with 
increases in cell density, DAT availability, and other neurobiological effects 
stated above. 
 
 
Animal Studies 
 
 In order to assess the behavioral and cognitive abnormalities found in 
addiction, animal models are commonly used to control for genetic, 
environmental, and pharmacologic factors that may be impossible to control for in 
human addicts. In particular, rodents treated with MA via contingent (non-
experimenter administered) or non-contingent (experimenter administered) 
methods are used to facilitate a better understanding of the brain regions that 
underlie MA addiction and to examine the effects of MA on tasks that assess 
cognitive domains that parallel human MA addicts. As mentioned above, animal 
studies have examined behavioral, neurobiological, and neurochemical changes 
after MA administration using a few different models. The common contingent 
model is self-administration of MA, which is specifically used to examine the 
reinforcing properties of the drug, including drug-seeking and drug-taking 
behavior. In this model, animals are allowed to self-administer for specific periods 
of time, such as one hour or 12 hours a day for up to two weeks. The self-
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administration method has more face validity than the non-contingent methods 
because humans self-administer MA; however, both self-administration and 
experimenter-administered methods have construct validity because the neural 
circuitry underlying the mechanisms of action of MA for both methods is reliably 
predicted (Steketee & Kalivas, 2011).   
 The most common human pattern of MA use is using 1-6 times a day 
(Homer   et   al.,   2008).   To   model   this,   “binge”   methods   consist   of   repeatedly  
injecting a rodent with MA several times within a short amount of time (Cho et al., 
2000). After completing this bingeing method, which is usually meant to induce 
neurotoxicity, many studies have looked at transporter and neurotransmitter 
levels and neurobiological changes including grey and white matter density. 
However, both binge and chronic regimens (such as behavioral sensitization: see 
behavioral sensitization), mimic human patterns of addiction, with one 
exemplifying bouts of injections and the other resembling repeated and long-term 
use of the drug (Belcher et al., 2008). Although there is a substantial amount of 
data on neurobiological and neurochemical alterations as well as cognitive 
impairments induced by MA after binge administration in rodents, chronic 
administration experiments are not frequently employed and there is a lack of 
literature on how chronic administration affects neurobiology and cognition, 
especially in a long-term  manner.  Additionally,  since   the  “binge”  pattern   is  most  
common in humans, chronic intermittent MA use might precede the transition to 
full-blown addiction, which makes exploring chronic use very important. Recent 
data suggests that MA-induced cognitive impairments may be a particularly 
    
 
13 
important feature of the addicted phenotype as impairments in this domain may 
reflect altered neurocognitive control of behavior, thus contributing to increased 
probability of relapse (Tapert et al., 2004; Reichel et al., 2011). However, only a 
few studies have examined possible recovery of cognitive functions after varying 
periods of abstinence after chronic administration regimens. Therefore, by 
characterizing the time course of changes in cognition that occur after chronic 
MA, we will better understand the brain regions and neural systems that are 
progressively impaired by MA and how they recover. 
 
 
Behavioral Sensitization    Behavioral sensitization is a useful method to examine how brain 
function is altered after repeated exposure to a substance. It is defined as an 
augmented psychomotor response with repeated administration of a 
pharmacological agent (Pierce & Kalivas, 1997). Sensitization yields a number of 
protracted changes in neurobiology and behavior, and has been shown to 
effectively model a number of the cognitive abnormalities found in addicted 
individuals (Fletcher et al., 2007). Sensitization can be separated into three 
phases: acute, which is the effects of the first injection of the drug, induction, 
which is defined as the neural events that occur immediately after the first few 
injections, and expression, which is defined as the long-term changes that occur 
after the injection (Robinson et al., 1998). However, initiation and expression can 
manifest during different times depending on the number of injections, the dose 
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of drug, the number of session, the pattern of injections, and the length of the 
withdrawal period from the drug (Phillips & Di Ciano, 1996).        
 A few methods, including conditioned place preference (CPP) or 
alterations in locomotor activity, are used to examine if an animal is sensitized to 
a drug (Steketee & Kalivas, 2011). In CPP, rats are sensitized to the drug if they 
spend more time on the side of the chamber that was previously paired with the 
drug.  This behavior identifies if the rat is sensitized to the motivational effects of 
the drug. Moreover, to explore motor activity, rats are placed in locomotor 
chambers and activity is recorded for a period of time. Then, locomotion and 
stereotypy are measured and used as indices of behavioral sensitization. 
Previous research shows that administering chronic doses of MA induces 
locomotor sensitization in rodents, suggesting that they have increased 
locomotor activity to the same dose of drug throughout drug administration 
compared to the animals that did not receive MA (Wang et al., 2012; Lee et al., 
2011). This phenomenon is reported to last at least a year (Paulson et al., 1991). 
With chronic treatment, MA shifts from inducing hyperactivity to stereotypy 
(Kuczenski et al., 2009; Fujiwara et al., 1987). Although dosing regimens differ 
from one study to the next, increased locomotor activity, and stereotypy (with 
higher doses), has been observed using various doses in rats, including 1.0, 2.0, 
2.5, 3.0, 5.0, and 10.0 mg/kg (Slamberova et al. 2011; Fujiwara et al. 1987; 
McDaid et al. 2006; Belcher et al., 2006; Brady et al. 2003; McGuire et al., 2011).  
Both increases in locomotor activity and stereotypy are observed after 
high doses of MA administration.  It is thought that these two behaviors compete 
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with one another, suggesting that there might be separate neurocircuits 
underlying each (Joyce et al., 1984; Segal & Mandell, 1974). It is important to 
consider the neurocircuitry involved in behavioral sensitization to determine the 
different pathways that mediate the expression of these two behaviors. Previous 
studies show that the mPFC, hippocampus (HC), ventral tegmental area (VTA), 
nucleus accumbens (NAcc), ventral pallidum (VP), amygdala, laterodorsal 
tegmentum, and parts of the thalamus are involved in the development of 
sensitization (Steketee & Kalivas, 2011). According to Pierce and Kalivas 
(1997a), a rodent that has never received a drug normally transmits DA from the 
VTA to the NAcc (mesolimbic pathway) and from the VTA to the PFC 
(mesocortical pathway). When a rodent is sensitized to a drug, there are changes 
in neurocircuitry, which include increases in dopaminergic transmission in these 
areas. Although there are other known projection pathways that likely contribute 
to behavioral sensitization, the ones mentioned above are the primary pathways 
driving sensitization.  
Studies have observed that increases in locomotor activity are 
predominantly due to psychostimulant-induced neuroplasticity of DA 
neurotransmission and DA receptors within the mesolimbic DA system. After 
injections of a psychostimulant, increased neurotransmission of mesolimbic DA, 
specifically to the ventral striatum, is observed (Koob & Volkow, 2010). 
Therefore, the dopaminergic projection via the mesolimbic pathway is what 
drives increases in locomotor activity. When inducing stereotypy, the basal 
ganglia (BG), which includes the caudate, putamen, and globus pallidus (GP), is 
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the most important mediator of the expression of stereotyped behaviors. 
Additionally, functions of the NAcc and olfactory tuberculum, as well as an 
overactive DA system, are involved in stereotyped behaviors (Nishikawa et al., 
1983; Costall et al, 1977). The BG consists of parallel cortico-basal ganglia loops 
that give rise to the limbic (ventral striatal pathway) and associative and 
sensorimotor (dorsal striatal pathway) circuits. In the ventral striatal pathway, 
there are direct and indirect pathways that disinhibit or inhibit movement, 
respectively (Alexander et al., 1986; Parent & Hazrati, 1995; Wolgin et al., 2012). 
Furthermore, GABA neurotransmission drives these differences in movement. In 
the direct pathway, GABAergic inputs from the GP to the thalamus disinhibit 
glutamatergic neurotransmission to the motor cortex, thereby increasing 
thalamocortical output and disinhibiting movement. In the indirect pathway, 
GABAergic inputs from the GP to the thalamus inhibit glutamatergic 
transmission, causing a decrease in thalamocortical output and an inhibition in 
movement. Taken together, GABAergic transmission, specifically from the GP, is 
involved in stereotyped behaviors. Furthermore, the direct pathway disinhibits 
movement whereas the indirect pathway inhibits movement, and this can 
possibly be associated with the differences in the expression of stereotypy.  
 Although there is support that locomotor activity is driven by the 
mesolimbic pathway and stereotypy is driven by the BG, Kelley et al. (1975) 
proposes that the mesolimbic DA pathway induces locomotor activity, and 
stereotypy is mediated by the nigrostriatal DA pathway. Since DA neurons in the 
nigrostriatal pathway prevent full functioning of mesolimbic neurons, locomotor 
    
 
17 
activity and stereotypy compete with one another (Joyce and Iverson, 1984). 
Taken together, the hypotheses of the expression of locomotor activity and 
stereotypy mentioned above by Wolgin et al. and Kelley et al. provide insight into 
the different pathways contributing to sensitization. It is important to consider this 
transition to stereotypy and the underlying neurocircuitry associated with it, 
because these changes in neurocircuitry after chronic intermittent use may model 
the transitional period from recreational use to binging in humans. Described 
below are the neurobiological and cognitive effects that MA induces after 
abstinence in rodents. With the exception of the neurobiological effects stated 
subsequently, the studies below all employed a sensitization regimen. 
 
 
Neurobiological Effects After Abstinence 
 
 Previous research suggests that the impairments of cognitive function 
following MA use in humans are caused by long-term or permanent changes in 
the neurobiology of the brain and all likely contribute to the neurophysiological 
changes observed in MA addicts. Many of these changes are also seen in the 
rodent after binge regimens, including reductions in brain DA and DAT levels in 
the ventral-caudate and putamen of the striatum (Chapman et al., 2001; Gross et 
al., 2011), and depletions in 5-HT and SERT levels in cortical, hippocampal, and 
amygdalar regions (Fukumara et al., 1998; Gross et al., 2011). Although few 
studies have observed neurobiological changes after employing sensitization 
regimens, a few studies have found reductions in DA and 5-HT in the PFC after 
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chronic MA administration (Ago et al., 2012 & 2007). It is unclear whether the 
cognitive deficits are due to the acute pharmacological effects of the drug, due to 
the neurotoxic changes brought upon by binge administration methods, due to 
long-term changes caused by sensitization, or if cognitive impairments can occur 
without the regimen causing neurotoxicity or long-term alterations in the brain. 
However, these changes in neurotransmission and neurobiology possibly 
contribute to the differences observed in cognition after repeated administration 
of MA in animals.  
 
 
Cognitive Effects After Abstinence 
  
 Similar to MA users, animals sensitized to MA exhibit impaired cognitive 
functions in tasks that examine attentional set-shifting (Parsegian et al. 2011), 
reversal learning (Kosheleff et al., 2012), and recognition memory (Kamei et al., 
2006; Belcher et al., 2008; Reichel et al., 2011). Although there are few studies 
to date that examine the cognitive effects of MA in rodent models after chronic 
use, it is important to examine each of the studies in detail since repeated use of 
the drug is a common pattern used in humans and understanding the brain 
regions that underlie the cognitive tasks where impairments are found is an 
active step in understanding addiction.   
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Set-Shifting 
 
 Set-shifting and behavioral flexibility tasks are used to identify deficits in 
the ability to switch from one cognitive domain to another and these tasks involve 
selective PFC functioning. A behavioral task commonly used in animals to 
examine behavioral flexibility is the attentional set-shifting task (ASST) that 
examines a series of cognitive functions such as working memory, procedural 
memory, and flexibility in performance strategy.  Impairments in set-shifting is 
demonstrated in an animal study by Parsegian et al. (2011), who observed that 
after a short-access (1-hour access for 7 days) followed by a long-access (6-hour 
access for 14 days) period of MA self-administration, rodents were impaired in 
the extradimensional shift portion of an attentional set shift task, which is a 
domain that measures flexibility in performance strategy, and involves the 
functioning of the mPFC.  
 
 
Novel Object Recognition (NOR)/Temporal Order Recognition (TOR) 
  
Impairments have also been observed in recognition memory. To examine 
the effects on NOR, the ability to detect novelty when given a novel or a 
previously encountered object, a study by Kamei et al. (2006) showed that mice 
that received 1.0 mg/kg of MA for seven consecutive days showed no 
impairments in NOR one hour after the last injection, but did 24 hours after the 
last injection. Since NOR was intact one hour after injection, this suggests that 
repeated administrations of MA may impair long-term retention of an object 
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without necessarily affecting short-term memory. These impairments lasted up to 
28 days. Additionally, Belcher et al. (2006) observed that rats that received 3.0 
mg/kg of MA every other day for 10 days showed a decrease in exploratory 
behavior toward the novel object in comparison to control subjects, although 
these differences were not significant. This took place one week after the last day 
of drug-administration. Conversely, Clark et al. (2007) examined rats that 
received a progressively increasing dose of MA for 14 days, followed by four 
daily injections of 6.0 mg/kg every two-hours for 11 days. They showed no deficit 
in NOR when compared to control animals. As suggested by the previous 
findings, this may be due to the ability of MA exposure prior to a binge regimen to 
attenuate some of the neurochemical and neurophysiological consequence of 
binge injections, including neurotoxicity and hyperthermia, by developing 
tolerance to the toxic effects of the drug during extended administration of MA 
(Riddle et al., 2002; Segal et al., 2003).   
 It is important to consider the brain regions involved in recognition memory 
to understand the neuroanatomical alterations that are driving the deficits in 
novelty detection after chronic MA use. Previous research suggests that rodents 
receiving bilateral lesions of the HC are impaired in the ability to detect novelty 
(Broadbent et al., 2010). Temporal memory, the ability to sequence events in 
time, is also a common way to measure cognitive impairments in memory in 
animals (DeVito & Eichenbaum, 2011). However, there are no animal studies 
that have examined impairments in temporal memory after a sensitizing regimen 
of MA. It is known that transiently inactivating the prelimbic regions of the PFC 
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(Hanneson et al., 2004) may impair temporal memory, whereas administering a 
D1 agonist peripherally may improve the ability of rodents to sequence the order 
in which objects were encountered and impair the ability to detect novelty (Hotte 
et al., 2005). Therefore, the aforementioned studies provide support that these 
two tasks require the proper functioning of the HC and PFC, and both involve the 
DA system. Also, the impairments found in NOR in the studies by Kamei et al. 
(2006) and Belcher et al. (2006) suggests that there may be dysfunctions in the 
HC that are mediating the impairments in novelty detection in these animals after 
chronic MA administration. 
 
 
Social Interaction (SI) 
 
 
Lastly, there are currently no papers published on the effects of MA on SI 
after a sensitizing regimen. Humans engage in SI, the mutual actions of two or 
more people oriented towards one another (Rummel, 1976), on a daily basis. 
Impairments in SI can be seen in individuals with depression, anxiety, autism or 
phobias. Decreases in SI are also seen in acute and chronic human abusers of 
psychostimulants (Miczek & Tidey, 1989). Since social interactions are a 
common part of everyday life, it is important to determine if MA has an effect on 
SI in rodents, and if it does have an effect, then it is important to examine if these 
decreases in SI are persistent or if they recover after abstinence.   
Regardless of the cause of these disturbances, whether or not they are 
due to social anxiety, depression, or autism, a decrease in SI may be due to 
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disruptions of different neuroanatomical sites, including the cerebral cortex, 
limbic system, and cerebellum (Adolphs et al., 2002; Bachevalier & Malkova, 
2006; Baron-Cohen et al., 2000). In animals, the efferent and afferent 
connections from the amygdala in the limbic system to the orbito-frontal cortex 
(OFC) and the mPFC are known to be the key substrates involved in social 
behaviors (Truitt et al., 2007). Therefore, impairments seen in SI in rats after MA 
administration may be due to disruptions of efferent and afferent connections 
between the amygdala and OFC and mPFC, although none of the above studies 
have examined these disruptions. Looking at SI in rodents after abstinence is 
crucial since it is speculated that the changes in social functioning that remain 
after abstinence in humans may be due to the long-term or irreversible structural 
changes that occur in the brain following MA use (Homer et al., 2008), and as 
mentioned above, these changes may be due to disruptions in the limbic system, 
cerebral cortex, and cerebellum.  
In conclusion, these findings in animal literature suggest that based on the 
dose, administration regimen, and period of abstinence from the drug, there may 
be different results when examining set-shifting and NOR. The next step is to 
observe if there are impairments in temporal memory and SI after a sensitizing 
regimen of MA to further explore the underlying substrates that are altered after 
MA use.  
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Statement of Purpose 
 
    MA is a dangerous drug that is highly prevalent and its use is on the 
rise, however, not much is known about the chronic effects of MA use, especially 
after early and prolonged abstinence. In these sets of studies, I first developed a 
regimen of MA that lead to robust sensitization. I hypothesized that chronically 
injecting 5.0 mg/kg of MA every other day for 14 days would generate an initial 
increase in locomotor activity transitioning into stereotypy as the sensitization 
regimen progresses. Secondly, I hypothesized that rats receiving 5.0 mg/kg of 
MA after 40 days of abstinence will have high stereotypy scores comparable to 
the scores on the last day of injection, which will suggest that rats are sensitized.  
After sensitization, I employed a set of behavioral and cognitive tasks that 
examined different domains of PFC and HC function after varying periods of 
abstinence to determine if there are MA-induced impairments in cognition. These 
tasks included TOR, NOR, and SI. TOR and NOR were selected as indices of 
PFC and HC mediated cognitive function, respectively. The SI task allowed the 
observation of social withdrawal that is also observed in human MA addiction. 
These tasks were chosen because, collectively, similar tasks that are mediated 
by the same brain regions are used to examine impairments across a range of 
behavioral and neurocognitive domains observed in human MA users 
(Kalechstein et al., 2003). I hypothesized that rats will have decreased SI after 
short and prolonged abstinence. Also, an acute injection of 5.0 mg/kg of MA 30-
minutes prior to experimentation will decrease SI in drug naïve animals. 
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Additionally, rats will be impaired in TOR and NOR after short and prolonged 
abstinence, suggesting that MA sensitization possibly causes impairments in 
PFC, HC, and perirhinal cortex functioning which persists up to 30 days. Lastly, 
these cognitive impairments will not be present after a single injection of MA in a 
group of drug naïve animals. By employing these tasks after varying periods of 
abstinence, I was able to determine if there were any type of recovery in 
cognition or if these impairments persisted chronically in these rodents and 
possibly, for MA addicts. Lastly, based on the cognitive impairments observed 
after employing cognitive tasks mediated by the PFC or HC, there is support that 
these regions, along with the DA system, may be differentially impaired 
throughout the time course of abstinence due to the impairments seen while 
undergoing these cognitive tasks.  
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METHODS 
 
 
 
Subjects 
 110 adult male (PND 63) Sprague-Dawley rats were purchased from 
Harlan Research Laboratories (Indianapolis, IN). At the time of arrival, animals 
weighed approximately 250-300 g. Since the SI task required two animals to 
interact with one another, animals were individually housed in polycarbonate 
cages   (10”x18”x8”)   throughout  all  experimentation   to  control   for   the  effects   that  
MA has on interacting with another rodent. These cages were filled with pine 
chips bedding and were kept in a climate-controlled room. Housing was 
maintained on a reverse 12:12 light/dark schedule (0700-1900 hours) so that 
testing occurred during the normal active (dark phase) of the awake/sleep cycle. 
Animals had ad libitum access to food and water throughout the experiments. 
Animals were handled one week for approximately 10-minutes per day to lessen 
the possibility of anxiety and to familiarize animals to human contact before all 
experiments. All experimentation was carried in accordance with Indiana 
University-Purdue University Indianapolis School of Science IACUC. 
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Drug Treatments  
 On the days of injection, rats were administered either Methamphetamine 
Hydrochloride (MA) or 0.9% saline solution (MA; Sigma Chemical Co., St Louis, 
Mo., USA) via intraperitoneal (i.p.) injection. MA solution was prepared on each 
day of experimentation. A slightly higher dose (5.0 mg/kg) of MA hydrochloride 
than Belcher et al. (2006) was used in this study to strengthen the probability of 
creating cognitive impairments. Lastly, although Brady et al. (2005) administered 
5.0 mg/kg of MA for five days and observed sensitization, more injections of MA 
was administered and for a longer period of time (two weeks) in these sets of 
experiments to generate robust sensitization. 
 
 
Behavioral Measures 
  
Methamphetamine Behavioral Sensitization 
 
 In Experiment 1, the induction of behavioral sensitization began one week 
after the animals arrived. Animals were administered either 5.0 mg/kg of MA (n = 
20) or 0.9% saline solution (n = 18) via i.p. injection every other day for 13 days 
(5.0 mg/kg x 7/13 days; induction phase). This regimen was chosen based on 
other studies that have shown that an every other day dosing regimen 
overcomes the neurotoxicity and long-term monoamine terminal deficits in the 
brain otherwise caused by binge regimens (Kuczenski & Leith, 1981; Nishikawa 
et al., 1983). Additionally, 13 days was chosen based on two studies that 
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observed an increase in locomotor activity and stereotypy after administering 4.0 
mg/kg (Ujike et al., 1989) or 6.0 mg/kg (Nishikawa et al., 1983) of MA for 13 
days. On the days of injection (days 1, 3, 5, 7, 9, 11, 13), animals were first 
acclimated   to   the  open  circular   locomotor  chambers   (21.5”  diameter  x  16.5”  H)  
for 60 minutes (acclimation). Animals were then injected with either MA or saline 
and placed back into the chamber for 60 minutes (testing). One week following 
the last day of induction, animals were given an injection of MA (5.0 mg/kg) or 
saline to verify sensitization (Figure 2). After all cognitive testing, rats received 
counter balanced MA (0.5 mg/kg, n = 12; 5.0 mg/kg, n = 8) or saline (n = 18) on 
two consecutive days (MA Challenge). Either 0.5 mg/kg or 5.0 mg/kg of MA was 
administered to examine whether or not rats would exhibit locomotor activity to 
the lower dose or stereotypy to the higher dose. On all days of injection, 
locomotor activity was recorded (ANY-maze, Wood Dale, IL) via video camera 
mounted above the chambers and the distance travelled (meters) was collected. 
Additionally, two observers manually scored stereotypy using a stereotypy rating 
scale adopted from Ellinwood Jr. & Balster (1974).  
 
 
Social Interaction (SI) 
  
 In Experiment 2, to examine the effects of MA on SI, rats were tested after 
one day (MA, n = 10; Saline, n = 8; Partner, n = 7) and 30 days (MA, n = 10; 
Saline, n = 9; Partner, n = 6) of abstinence after the induction phase described in 
Experiment 1. Two days before the experiment, all animals were individually 
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habituated in the open field chamber for 10 minutes. The chamber was 
illuminated with a red light similar to the light in their home cage during their dark 
cycle. SI was assessed using partner rats that were age, gender, and weight 
matched. Each partner rat was also was used in no more than three test 
sessions and had at least 40 minutes between running each session. On testing 
day, one partner rat was placed in the open field chamber followed by the 
experimental rat. The two animals were left in the open field chamber for 10 
minutes and interaction was recorded using ANYmaze via a video camera 
mounted above the chamber. After 10 minutes of recording, animals were placed 
back into their home cages. Each video was manually scored using the methods 
of Truitt et al. (2007). To assess test validity on SI, naïve adult Sprague-Dawley 
rats (n=22; received on PND 90) were used as a positive control to ensure that 
an effect would also be produced with the 5.0 mg/kg dose of MA, as seen with 
the 0.5 mg/kg-1.5   mg/kg   doses   in   the   studies   by   Šlamberová   et   al.   (2010   &  
2011). Rats were handled for 10 minutes each day for one week. Two days 
before the experiment, animals were individually habituated in the chambers as 
described above. On testing day, rats were injected once with MA (n = 8) or 0.9% 
saline solution (n = 8). Six of the remaining rats were used as partner animals 
and paired with an experimental rat based on weight. Thirty-minutes after the 
injection, SI was assessed as described above. 
    
 
29 
Temporal Order Recognition (TOR) 
 
In Experiment 3, rats were tested for temporal order memory (the ability 
for animals to remember the order of objects in which they had experience)- one 
day (MA, n = 8; Saline, n = 7) or 30 days (MA, n = 10; Saline, n = 9) following the 
induction phase in the same open field chamber used in the SI experiments. 
Velcro was applied on two opposite sides of the chamber, approximately 6.5 
inches  from  the  corner  of  the  box.  The  objects  included  two  rubber  ducks  (3.2”  x  
2.5”),  two  Rubik’s  cubes  (2.3”  x  2.3”x  2.3”),  and  two  circular  open  white  cups  (3”  x  
1.8”).  The order that animals experienced the objects was randomized to control 
for differences in object effects. On testing day, animals were placed in the open-
field chamber for 4 minutes and were able to explore two identical objects. After 
a 1-hour inter-trial interval, they were placed in the chamber with two identical 
objects different than the ones experienced previously and rats were able to 
explore for another 4 minutes. After a 45-minute inter-trial interval, rats were 
exposed to two objects, one from each previous trial for another 4 minutes. The 
amount of time (seconds) that an animal interacted with an object was recorded. 
 
 
Novel Object Recognition (NOR) 
 
 
 Immediately after TOR, recognition memory (the ability for animals to 
discriminate between novel and familiar objects) was examined. Testing took 
place in the same open-field chamber as the previous experiment after a 45-
minute inter-trial interval. Animals were placed in the chamber with the last object 
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encountered along with a novel object, and then were aloud to explore for four 
minutes. The amount of time each object was explored (in seconds) was also 
examined as described above (See Temporal Order Recognition). To examine 
whether or not the impairments seen after one day of abstinence were due to the 
sensitizing regimen, a naïve group of rats were injected with 5.0 mg/kg of MA (n 
= 8) or 0.9% saline solution (n = 11) and locomotor activity was recorded 60 
minutes pre- and post-injection. The next day, TOR and NOR were observed. If 
rats that received an acute injection of MA had impairments in TOR and NOR, 
this would suggest that an injection of MA one day before testing, whether it 
being the last day of the induction phase or an acute injection, may contribute to 
the impairments seen in the two cognitive tasks. 
 
 
Euthanasia  
 Animals were properly sacrificed in accordance with NIH guidelines and 
methods approved by the IUPUI School of Science IACUC. After animals were 
done with experimentation, they were individually placed in CO2 chambers for 
approximately 10-minutes while still in their cages. After 10 minutes, animals 
were removed and reflexes (including toe/tail pinch and shallow breathing) were 
examined. Once animals were dead due to the CO2, they were decapitated using 
a guillotine to physically ensure death. They were then transferred into the 
freezer.  The methods are well established and shown to be painless and quick, 
causing little or no discomfort to the animals. 
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Analyses 
 For Experiment 1, the distance travelled (meters) and counts of stereotypy 
were analyzed using repeated-measures ANOVA with treatment as a between-
subjects factor and days as the within-subjects factor. For stereotypy, the first 
minute of every five- minute bin was collected and averaged between the two 
scorers (12 bins for each day). Then, the average of the 12 bins for each animal 
was calculated. Lastly, the stereotypy score for that day was calculated by taking 
the average score for each animal on that day. Repeated-measures ANOVA was 
used to examine differences between treatment groups at 5-minute bins on Day 
1 vs. Day 21. A two-factor ANOVA was used to examine locomotor and 
stereotypy data from the MA challenge experiment. In Experiment 2, SI was 
analyzed using unpaired t-tests comparing the MA-treated groups with the saline-
treated groups at the three different time points (1-day abstinence, 30-day 
abstinence, acute injection). In order to analyze the data for TOR and NOR 
(Experiment 3), total time spent with each object was examined using a two-
factor ANOVA. Bonferroni post-hoc   comparisons  or  Tukey’s   LSD  were  used   to  
examine sub-group differences when applicable.  
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RESULTS 
 
 
 
Experiment 1: Methamphetamine Behavioral Sensitization 
 
 Intermittent treatment with MA significantly increased locomotor activity 
post-injection compared to saline-treated rats (main effect of treatment (F(1, 238) = 
15.94, p < 0.0005) and day (F(7,238)  = 5.853, p < 0.0001), as well as a treatment 
by day interaction, (F(7,238) = 3.176, p < 0.005). Bonferroni post-hoc analyses 
revealed significant differences in locomotor activity on days 1, 3, 5, and 9 in 
saline versus MA treated animals (Figure 3A). However, as the induction phase 
progressed, MA-treated rats exhibited a decrease in locomotor activity and an 
increase in stereotypy (Figure 3B), with a main effect of treatment (F(1, 138) = 
1170, p < 0.0001) and day (F(7,138)  = 4.53, p = 0.0001), and a treatment by day 
interaction (F(7,138) = 5.282, p < 0.001). Bonferroni post-hoc analyses revealed 
significant differences in stereotypy in saline versus MA treated animals on all 
days of the induction phase. Additionally, Bonferroni post-hoc comparisons also 
revealed significant increases in stereotypy on Days 7, 9, 11, 13, and 21 
compared to stereotypy on Day 1 in the MA-treated rats.   
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 When examining locomotor activity in 5-minute bins on Day 1 of treatment, 
rats that received MA significantly increased locomotor activity compared to 
saline-treated rats (main effect of treatment, F(1,110) = 7.431, p < 0.05). Bonferroni 
post-hoc analyses revealed significant differences in locomotor activity in saline 
versus MA during the 45-minute bin (Figure 4A). When examining 5-minute bins 
on Day 21 of treatment, MA rats exhibited an initial increase in locomotor activity 
that transitioned into a decrease in locomotor activity compared to saline-treated 
rats (time by treatment interaction, F(11,110) = 2.815, p < 0.005). Bonferroni post-
hoc analyses revealed significant differences between MA and saline only during 
the first time point at 5 minutes (Figure 4B). Lastly, when comparing locomotor 
activity in MA-treated rats on Day 1 and Day 21, MA-treated rats showed a 
significant increase in locomotor activity on Day 1 compared to the same rats on 
Day 21 (time by day interaction, F(11,110) = 2.998, p < 0.005 (Figure 4C). 
Bonferroni post-hoc analyses revealed significant differences in locomotor 
activity between Day 1 and Day 21 during the 40, 45, 50, 55, and 60-minute time 
points.  
 Figure 5 shows the path of the animal for a saline-treated animal (top) and 
a MA-treated animal (bottom) on day 1 (left) and day 21 (right) of the induction 
phase. It seems that the MA-treated animal had robust locomotor activity initially 
on day 1, but after the injection on day 21, locomotor activity substantially 
subsided. The saline animal remained similarly activity on day 1 and day 21 of 
the induction phase. Although not shown, this suggests that the decrease in 
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locomotor activity depicted by the activity path in the MA animal on day 21 may 
be due to the fact that the animal is exhibiting stereotypy.   
Approximately 30 days after the induction phase, rats received 
counterbalanced injections of MA (0.5 mg/kg or 5.0 mg/kg) or saline. Following 
0.5 mg/kg of MA, both chronic saline-treated and chronic MA-treated rats showed 
an increase in locomotor activity compared to rats that received saline (Figure 
6A), (main effect of treatment, F(1,42) = 25.67, p < 0.0001). Bonferroni post-hoc 
analyses revealed significant differences in injection for chronic MA-treated (p < 
0.001) or saline-treated (p < 0.05). There were no differences in stereotypy in 
either of the treatment groups when given this dose (Figure 6C). When rats 
received 5.0 mg/kg of MA, there was a significant increase in locomotor activity 
only in the chronic saline- treated group that received MA, with a main effect of 
treatment (F(1,26) = 8.845, p < 0.05), main effect of acute injection (F(1,26) = 11.65, 
p < 0.005), and a treatment by injection interaction (F(1,26) = 8.993, p < 0.05). 
Bonferroni post-hoc analyses revealed significant differences in injection for 
chronic saline-treated (p < 0.001) group (Figure 6B). Significant differences were 
also observed when examining stereotypy in both treatment groups, (main effect 
of treatment, F(1,24) = 46.39, p < 0.0001 and injection (F(1,24) = 8.682, p < 0.05).  
Bonferroni post-hoc analyses revealed significant differences in injection for 
chronic MA-treated (p < 0.001) and chronic saline-treated (p < 0.001) rats (Figure 
6D). 
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Experiment 2: Social Interaction 
 
 No significant differences in SI were observed between MA- and saline-
treated rats after one day (Figure 7A) or 30 days (Figure 7B) of abstinence 
following the induction of behavioral sensitization. With acute treatment, rats 
receiving an injection of MA (5.0 mg/kg) exhibited a significant decrease in the 
amount of SI time compared to the rats that received a single injection of saline 
(Figure 7C, unpaired t-test, t(14) = 7.649, p < 0.0001).  
 
 
Experiment 3: Temporal Order and Novel Object Recognition 
 
 
One-Day Abstinence  
 
 In Experiment 3, MA-treated, but not saline-treated rats were significantly 
impaired in TOR main effect of order, F(1,26) = 4.443, p < 0.05) (Figure 8A), and in 
NOR ( main effect of order, F(1,32) = 4.920, p < 0.05) (Figure 9A), and a 
treatment by order interaction, (F(1,32) = 5.878, p < 0.05) after one day of 
abstinence. This suggests that MA-treated rats were not able to sequence events 
in time and were not able to detect novelty after one day of abstinence from MA. 
Tukey’s  LSD  revealed  significant  differences  in  order in the saline-treated group 
during TOR, t(6) = 6.094, p = 0.0004) and during NOR, t(7) = 3.272, p = 0.0068. 
This suggests that there was only a significant difference in the saline-treated 
animals in the amount they spent with one object over the other.  
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Thirty-Day Abstinence 
 
 After 30 days of abstinence, MA-treated, but not saline-treated rats, were 
significantly impaired in TOR ( main effect of order, F(1,34) = 10.03, p < 0.005) 
(Figure 8B). One-tailed, paired t-tests revealed an order effect in the saline-
treated group, t(8) = 4.507, p = 0.001. This indicates that saline-treated rats 
preferred the older object significantly more than the recent object. Since this 
effect was not seen in MA-treated animals, it suggests that chronic MA animals 
still have impairments in TOR after extended abstinence. Both MA- and saline-
treated rats exhibited NOR (Figure 9B) after 30 days of abstinence (main effect 
of order, F(1,34) =  22.33,  p  <  0.0001).  Tukey’s  LSD  revealed  significant  differences  
in the order of the object in both the saline, t(8) = 2.716, p = 0.0132and MA, t(9) = 
3.738, p = 0.0023. 
 
 
Single Injection 
 
 
 One day after a single injection of saline or MA, an increase in time spent 
exploring the older object relative to the recent was observed in both treatment 
groups, indicating that rats receiving either a saline or MA injection exhibited 
TOR (main effect of order, F(1,34) = 14.04, p < 0.005) (Figure 10A). When 
examining NOR, both groups spent more time with the novel object versus the 
recent object, (main effect of order, F(1,34) = 6.60, p < 0.05) (Figure 10B). Lastly, a 
main effect of treatment (F(1,34)= 7.256, p < 0.05) was observed in the NOR 
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experiments indicating that while a bias in exploring the novel object existed, the 
MA animals spent less time exploring either object overall. 
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DISCUSSION 
 
 
 
The goal of this study was to first induce behavioral sensitization in rats 
via repeated intermittent injections of MA, and then determine whether or not 
chronic MA administration caused temporally distinct impairments in cognitive 
function after short-term and long-term abstinence. In the behavioral sensitization 
studies, there was an initial increase in locomotor activity that eventually 
transitioned into stereotypy. An examination of the short-term impairments in 
cognition revealed that rats were impaired in temporal sequencing and novelty 
detection. Rats were still impaired in temporal sequencing, but not novelty 
detection, after extended abstinence. The impairments seen after short-term 
abstinence were not due to the acute effects of MA, but due to the sensitizing 
regimen and possibly the long-term neuronal changes caused by chronic 
intermittent injections of the drug. When examining SI, there were no differences 
between saline-treated and MA-treated rats after short or extended abstinence, 
but there were significant decreases in SI in the MA-treated rats after an acute 
injection of MA 30 minutes before the SI task. Lastly, rats were still sensitized to 
the drug ~40 days after the end of the induction phase, which supports that the  
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impairments seen in temporal memory after extended abstinence may be due to 
the long-term and persistent effects of MA. 
 
 
Locomotor Activity and Stereotypy During the Induction Phase 
 
 
 The hyperlocomotion observed in this study is similar to what others have 
observed after varying doses of peripherally delivered MA. However, studies that 
used lower doses have only seen increased locomotor activity, but have not 
reported increases in stereotypy. For example, in a study by Zakharova et al. 
(2009), rats that received 0.5 mg/kg once daily for 5 days showed an increase in 
locomotor activity compared to saline rats, but rats that received 0.125 mg/kg of 
MA showed locomotion similar to those that received saline. This suggests that a 
slightly higher dose of MA increased locomotor activity in the rats chronically 
treated with MA. Hyperlocomotion is also observed when administering 
moderately higher doses of MA. For example, rats that received 1.0 mg/kg of MA 
every day for 10-14 days showed elevated locomotor activity as the injections 
progressed (Wang et al. 2012; Meyer et al., 2011; Futamura et al., 2011). There 
were no reports of stereotypy in any of the studies. Taken together, these studies 
suggest a dose-dependent manner in which locomotor activity is expressed. 
When looking at the locomotor data in the experiments that I have conducted, 
MA induces locomotor activity initially, but unlike the aforementioned studies, 
transitions into stereotypy. The differences between our studies may be due to 
differences in the length of drug administration and dose administered. When 
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considering the experiments below that examine locomotor activity and 
stereotypy, it is apparent that the two behaviors begin to compete when MA is 
administered at higher doses. It is important to assess how various doses 
differentially affect locomotor activity and stereotypy to reach a better 
understanding of what is driving decreased locomotor activity and increased 
stereotypy in the experiments that I have conducted. 
 Moderate to higher doses of MA induce stereotypy. This is apparent in a 
study by Ujike et al. (1989) who observed progressively augmented locomotor 
activity and stereotypy in rats that received 4.0 mg/kg of MA for 14 days. To 
examine what was driving stereotypy, rats were administered a selective D1 or D2 
antagonist, which were both shown to reverse the effects of stereotypy while 
inducing hyperlocomotion, suggesting that the DA system is crucial to induce 
stereotypy. This further supports the hypothesis that the nigrostriatal pathway 
may be involved in stereotypy and the mesolimbic pathway may be involved in 
the expression of locomotor activity, since D1 receptors are most abundantly 
expressed in the nigrostriatal pathway (Neve et al., 2004), and antagonizing the 
receptors in this region may decrease basal ganglia functioning, which includes 
motor control and stereotypy.  
  Studies have also shown differences in the onset of stereotypy within a 
sensitizing regimen when administering 4.0 mg/kg of MA for 7 days (Szumlinski 
et al., 2000) or 6.0 mg/kg of MA for 14 days (Nishikawa et al., 1983) to rats. 
When going back to Figure 4C, rats that received MA on day 21 have a 
significant decrease of locomotor activity after 5-minutes compared to locomotor 
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activity on day 1. This is when stereotypy possibly dominates locomotor activity, 
suggesting a shorter onset of latency of stereotypy compared to day 1 of 
injections. Lastly, Tsukamato et al. (2001) observed a dose response function 
when rats exhibited locomotor activity or stereotypy. In this study, rats that 
received 2.0 mg/kg of MA showed the highest locomotor activity compared to 
saline or to rats that received 1.0 mg/kg, 4.0 mg/kg, or 8.0 mg/kg of MA. When 
examining stereotypy, rats that received 8.0 mg/kg of MA showed the highest 
stereotypy scores. These scores decreased with lower doses. These data clearly 
support that the differences observed (locomotor activity vs. stereotypy) in the 
aforementioned studies are due to the difference in doses between the studies. 
For example, the higher doses of MA induce stereotypy, a phenomena that is not 
seen in the lower doses.  
 
 
Locomotor Activity and Stereotypy During the MA Challenge 
 
 
 Similar results have been observed in response to a MA challenge. For 
example, rats that received 3.0 mg/kg of MA every 3 days for a total of 5 
injections, followed by a challenge dose of 0.5 mg/kg, had increased locomotor 
activity compared to chronic saline-treated rats that received 0.5 mg/kg of MA on 
the challenge day (Yang et al., 2006). Additionally, Brady et al. (2005) 
administered 5.0 mg/kg of MA every day for 5 days followed by 0.5 mg/kg of MA 
as a challenge dose, and observed that the MA-sensitized rats had increased 
locomotor activity compared to the chronic saline-treated rats that received a MA 
    
 
42 
challenge dose. This was also observed in the experiments that I conducted. 
Chronic MA rats that received 0.5 mg/kg of MA during the MA challenge had 
higher locomotor activity compared to the chronic saline-treated rats that 
received 0.5 mg/kg of MA. However, when administered a higher 5.0 mg/kg 
challenge dose, the MA rats had decreased locomotor activity and higher 
stereotypy. This was also seen in rats that received 6 mg/kg of MA once daily for 
14 days, followed by a challenge dose of 1.0 or 1.75 mg/kg 65 days after the 
sensitization regimen (Nishikawa et al., 1983). The results showed that 5% of 
animals receiving 1.0 mg/kg showed stereotypy and 100% of rats that received 
1.75 mg/kg showed stereotypy. This suggests that the closer the challenge dose 
to the original dose used during sensitization, the more likely rats would exhibit 
stereotypy. 
 As a conclusion, although dosing regimens differ from one study to the 
next, increased hyperlocomotion, and stereotypy (with higher doses) have been 
observed using various doses in rats, including 1.0, 2.0, 2.5, 3.0, 5.0, and 10.0 
mg/kg (Slamberova et al., 2011; Fujiwara et al., 1987; McDaid et al., 2006; 
Belcher et al., 2006; Brady et al., 2003; McGuire et al., 2011). Both 
hyperlocomotion and stereotypy were also observed in these studies, which 
confirm that rats were behaviorally sensitized to MA. 
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Social Interaction  
 
 To date, there are no studies published on chronic MA administration and 
SI in animals. This may be due to the observations in these experiments that SI 
is not reduced in MA-treated animals after repeated 5.0 mg/kg injections one day 
and 30 days after abstinence. For example, after one day of abstinence, saline-
treated rats spent ~120 seconds and MA-treated rats spent ~115 seconds out of 
300 seconds interacting with partner rats. There were no differences in SI time 
between the two groups. The same pattern is seen after 30 days of abstinence. 
Saline-treated rats spent ~115 seconds and MA-treated rats spent ~100 seconds 
interacting with a partner rat. Again, no significant differences were seen 
between the two treatment groups in SI after prolonged abstinence.  
 Although I did not find differences in SI after repeated injections of MA, a 
binge study by Clemens et al. (2004) observed decreases in SI in MA-treated 
rats 4 weeks after the treatment.  Rats were injected with saline or MA (2.5 
mg/kg or 5.0 mg/kg) every two hours for a total of four injections. Four weeks 
later, rats were assessed on SI. They found that both doses of MA decreased SI 
significantly more than in the saline-treated animals. Also, based on the results of 
an emergence test in the same study, MA-treated rats had increased anxiety 
after four weeks of treatment compared to saline-treated rats. The caveat in this 
experiment was that during SI, a MA-treated rat was paired with another MA-
treated rat and a saline-treated rat was paired with another saline-treated rat, 
which introduces the possibility that when an anxious MA rat was paired with 
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another anxious MA rat, that there was an additive effect on anxiety toward one 
another, thereby decreasing SI in the MA-treated groups.  
 When examining the data presented herein, SI was not significantly 
different or decreased compared to the saline-treated rats after abstinence, 
although SI was decreased after 30 days of abstinence in the binge study 
described above. The differences in results collectively suggest a few 
possibilities; that the brain regions thought to be responsible for SI, specifically 
the OFC and mPFC, may not be altered after long periods of chronic MA 
administration, but may only be altered after binge regimens that are thought to 
cause neurotoxicity to the brain. Lastly, it is possible that regions other than the 
OFC and mPFC, such as the amygdala (Amaral, 2006), contribute to social 
interactions, and these structures are altered, causing decreases in SI after binge 
administrations. It is important to note that these are all speculations, given that I 
have only conducted behavioral experiments in these animals and have not 
simultaneously measured the biological or neurochemical underpinnings 
associated with SI. Future studies may potentially include examining protein 
levels of DA, SERT, NE, and GLUT using immunohistochemistry and transmitter 
levels using microdialysis.  
 When examining SI 30 minutes after an acute injection of MA, there was a 
significant decrease in SI compared to the animals that received saline.  During 
SI, rats were still under the influence of MA since the half-life of MA is one hour. 
These results suggest that a rodent exhibits decreases in SI while under the 
influence of 5.0 mg/kg of MA. This has also been observed in two studies by 
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Slamberova et al. (2010 & 2011), who administered 0.5, 1.0, or 1.5 mg/kg of MA 
30 minutes prior to a SI task and found a decrease in SI after a MA injection 
compared to rats injected with saline. The differences in SI may be due to the 
anxiogenic effects that are brought upon by stimulant drugs (Ettenberg and 
Geist, 1991). When watching the videos, the partner rats were trying to interact 
with the MA-treated rats, but the MA-treated rats would quickly escape from 
interacting. If MA-treated rats were experiencing anxiety, then it is very likely that 
they did not want to interact. However, the saline-treated rats may be 
experiencing anxiety as well, since they interacted for an average of ~70 
seconds, which is less than the interaction time of saline-treated rats after one 
day and 30 days of abstinence. SI time in these animals was decreased 
compared to one day and 30 days of abstinence, possibly due to the fact that 
animals have only been exposed to human handling for one week. The rats in 
the one-day and 30-day experiments were sensitized and not only handled 
during the one-week handling period, but also had contact with humans during 
the sensitization phase. It may be possible that the animals in the single injection 
group were merely stressed due to handling or to a situation that they were not 
used to, such as being in an open field, although they were exposed to the open 
field for 10 minutes a day for two days. Lastly, it is important to note that all SI 
experiments took place in the same open field so there were no contextual 
differences from one experiment to the next. 
 In conclusion, SI was not decreased in chronically-treated MA rats after 
one day or 30 days of abstinence, but was decreased 30 days after a binge 
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regimen (Clemens et al., 2004). This could be due to the difference in 
administration, such that the chronic intermittent injections of MA may not be 
causing neurotoxicity that is otherwise caused by binge regimens. Lastly, SI was 
decreased 30 minutes after an acute injection of MA, which was also seen by 
Slamberova et al. (2010 & 2011). It is speculated that the acute decreases may 
be due to the anxiogenic effect that MA has on SI. 
 
 
Temporal Order Recognition 
 
 
 There are no previous studies that have examined TOR after repeated MA 
exposure. In these sets of experiments, impairments in TOR were observed after 
one day and 30 days of abstinence following a sensitizing regimen of MA. As 
mentioned previously, the prelimbic region of the PFC is critical in mediating 
temporal memory, since inactivating this region impairs temporal sequencing in 
rodents. Additionally, PFC damage in rats (Kesner & Holbrook, 1987) and in 
monkeys (Petrides, 1991) can disrupt temporal memory. Collectively, those 
findings suggests that the impairments observed in this study could be due to 
alterations in PFC functioning, specifically in the prelimbic area.   
Impairments in TOR were also observed after up to 30 days of abstinence 
in the MA-treated rats, which suggests that the sensitization regimen had a 
persistent effect on the PFC. The long-lasting effect in this region impaired the 
MA-treated   rats’   ability   to   sequence   events   in   time,   thereby impairing temporal 
memory. Although the specific neurochemical and neurobiological underpinnings 
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contributing to these impairments after inactivating (by lesioning or antagonizing) 
the prelimbic area is unclear, a recent article suggests that inactivation of the 
prelimbic region was paralleled with exaggerated synaptic plasticity, the 
phenomenon of synaptic circuits being strengthened or reorganized (Baudin et 
al., 2012). Changes in synaptic plasticity have also been observed in the HC-
mPFC pathway by Ishikawa et al. (2005), who administered 4.0 mg/kg of MA to 
mice for four consecutive days. MA caused a decrease in D1 receptors due to its 
ability to increase long-term extracellular DA. Since the mPFC plays a crucial role 
in working memory (Kesner et al., 2005) and D1 receptors are essential for 
cognitive function (Seamans et al., 1998), these studies collectively suggest that 
the DA system plays a major role in synaptic plasticity within the mPFC.  In the 
mPFC, synaptic plasticity is also demonstrated after repeated injections of 
amphetamine. For example, Morshedi et al. (2009) observed an increase in the 
number of excitatory synapses onto dendritic spines. Also, Robinson and Kolb 
(1999) observed increases in the length of dendrites and increases in spine 
density in pyramidal neurons in the mPFC, which increases the ability for 
neurons to communicate with one another since there is more room on the 
neuron for additional synaptic contact. Collectively, these studies support the 
idea that amphetamines induce changes in synaptic plasticity or changes in the 
morphology of neurons, which in turn allows neurons to be more available to 
receive excitatory or inhibitory input from other cells since there are more 
available areas on a neuron (such as on the spines) for additional excitatory 
synaptic contact.  
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 Another possibility contributing to the impairments seen in temporal 
memory after both time periods of abstinence may be MA-induced changes in 
neuronal firing rate. When observing the acute effects of MA, Jang et al. (2007) 
observed that a single dose of 4.0 mg/kg of MA showed a bidirectional and 
transient effect on firing rate. Shortly after the MA injection, neurons in the mPFC 
had an increase in firing rate; however, after 60 minutes, cells either increased or 
decreased firing rate. These different effects may be due to simultaneous 
inhibitory input to this region, as well as an increase in DA in this area (Jang et 
al., 2007). Also, Jodo et al. (2003) observed that after injecting rats acutely with 
1.5 mg/kg of MA, there was no apparent increase or decrease in firing rate in the 
mPFC compared to saline controls. When observing the effects of chronic MA on 
firing rate, the results are different. For example, Parsegian et al. (2011) 
observed that rats that self-administered MA for 21 days showed an increase in 
basal firing frequency of pyramidal cells in the mPFC 11 days after abstinence 
compared to control rats that received yoked saline. Chronic MA not only altered 
firing rate of pyramidal cells in these animals, but these neuronal changes were 
paralleled with impairments in behavioral flexibility demonstrated by the 
Attentional Set-Shift Task (ASST). This suggests that chronic MA caused deficits 
in cognition, which was also associated with changes in basal firing rate. 
Although the aforementioned studies found different results when examining MA-
induced firing rate in the mPFC, it is important to note that they all used 
drastically different administration paradigms before recording neuronal activity. 
For example, Parsegian et al. (2011) looked at firing rate after 21 days of MA 
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self-administration, which is very different than the effects that MA has on the 
brain and on firing rate after a single injection. Also, the other two studies 
observed firing rate after a single injection of MA, one study was using a fairly 
low dose of MA, whereas the other was using a high dose of MA.  
 Although much is unknown about firing rate in the PFC after acute or 
chronic MA exposure in an anesthetized or awake-behaving animal, there is 
much more consistent support for alterations in firing rate in rats that have 
received amphetamine. For example, Gulley and Stanis (2010) have observed 
that awake-behaving rats exhibited decreases in firing rate of PFC neurons after 
a single injection of 1.0 mg/kg of amphetamine. These inhibitory responses were 
also observed in the same rats after repeated exposure to amphetamine. 
Decreased firing rate in the PFC has also been observed in anesthetized rats 
that had received 1.0 or 2.0 mg/kg of amphetamine (Mora et al., 1976). However, 
when injected with a smaller dose such as 0.5 mg/kg of amphetamine, excitatory 
responses have been observed (Homayoun & Moghaddam, 2006). Collectively, 
these studies suggest that amphetamines cause changes in firing rate, whether 
be it an increase or a decrease, based on the administration paradigm and dose 
administered. These changes in firing rate are also associated with deficits in 
cognition, which may be contributing to the impairments seen in temporal 
memory after a sensitizing regimen of MA.  
 To examine if the impairments in cognition observed after one day of 
abstinence were due to the acute effects of MA administration or due to the long-
term neurochemical or neurobiological changes caused by the sensitizing 
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regimen, I injected a naïve group of rats with a single injection of 5.0 mg/kg of 
MA and tested them on TOR one day after the injection. The single-injection 
effect on TOR supports the speculation that chronic administration of MA caused 
these alterations in PFC functioning. Since there were no differences in TOR 
after a single injection of MA, this suggests the impairments seen in cognition 
were not due to the acute effects of MA after one day of abstinence, but were 
actually due to the sensitizing regimen itself. Furthermore, this suggests that a 
single injection of MA is not enough to induce synaptic plasticity in the prelimbic 
area, thereby not causing impairments in temporal memory. Additionally, 
changes in firing rate are not expected at this time point since the studies 
mentioned above examined MA-induced firing rate while the animals were under 
the influence of MA or after repeated exposure of the drug, which does not 
coincide with when I examined TOR in this experiment. This provides further 
support for my findings that the cognitive impairments observed after the 
sensitizing regimen were not due to the acute effects of MA, but due to the long-
term neuronal changes caused by MA.   
 In conclusion, it is possible that the impairments in temporal memory seen 
after one day or 30 days of abstinence are due to MA-induced changes in the 
functioning of the prelimbic area. Additionally, the sensitizing regimen may be 
causing long-lasting changes in synaptic plasticity and alterations in firing rate of 
PFC neurons, which could also be contributing to the memory deficits observed 
in these rodents. However, since we have not examined neurotransmission or 
the underlying mechanisms that are contributing to the impairments in these 
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areas, it is difficult to make a statement on the neurobiological changes that are 
driving these impairments in cognition. In conclusion, it is possible that the long-
term cognitive deficits seen in humans who chronically abuse MA (Salo et al., 
2009 & 2011) may be due to functional alterations in the mPFC, including 
synaptic plasticity or changes in the firing rate of PFC neurons, although these 
hypotheses need to be further assessed.  
 
 
Novel Object Recognition 
 
 
  To examine if there were impairments in recognition memory, I tested 
NOR in rats after one day and 30 days of abstinence following sensitization. 
Interestingly, impairments in NOR were observed in MA-treated rats after one 
day of abstinence, but not after 30 days of abstinence. Saline-treated rats were 
able to detect novel objects at the two time points, and, therefore, had no 
impairment in NOR throughout experimentation. 
 There are no studies that examine short-term effects on novelty detection 
associated with chronic MA administration. However, a few studies have 
observed impairments in NOR after an abstinence period from MA. Belcher et al. 
(2006) looked at NOR after one week of abstinence and found decreased NOR 
in the MA-treated rats compared to the saline rats, although differences were not 
significant. Although we did see impairments in NOR after one day of abstinence, 
impairments did not persist for 30 days. It is important to note that unlike Belcher 
et al., I only tested NOR after one day and at 30 days of abstinence, but did not 
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examine novelty detection at one week. It is possible that they did not find 
significant effects in their experiments because the rats were starting to regain 
their recognition memory a week after abstaining from MA and the effect was not 
strong enough to induce significant impairments in this domain. It is also difficult 
to compare my experiments to the experiments by Belcher et al. because there 
were a few differences in our studies. For example, they employed a shorter 
sensitization regimen with a lower dose of MA. They administered 3.0 mg/kg of 
MA every day for 10 days, whereas I administered 5.0 mg/kg of MA every other 
day for 14 days. Perhaps the dose they administered was not potent enough to 
induce significant impairments in novelty detection after one week of abstinence.  
Taken together, it is difficult to ascertain at exactly what point the impairments in 
cognition started to recover in my set of experiments because I did not test any 
days that fell between one day and 30 days of abstinence from MA. 
 As mentioned previously, MA-treated rats showed a recovery of 
recognition memory after 30 days of abstinence. These findings were different 
than the findings by Kamei et al. (2006) who showed that after receiving 1.0 
mg/kg of MA for seven consecutive days, mice were impaired in novelty 
detection after one day and 28 days of abstinence. Although I did not find 
differences in NOR after extended abstinence, there are many differences 
between our studies that may lead to the differences in results. First, the 
sensitization regimen was different. They administered MA consecutively for one 
week, whereas I administered MA intermittently for two weeks. I employed an 
every other day injection paradigm to allow for MA to be cleared from the system 
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substantially before the next injection, because accumulation of residual MA can 
cause neurotoxicity. However, and as mentioned previously, I cannot be sure if 
the sensitization regimen did not induce neurotoxicity. Another difference 
between our studies was that I tested NOR in rats, whereas they tested novelty 
detection in mice. Rats and mice have different metabolic rates, considering that 
the LD50 for MA in mice is 57.0 mg/kg and 55.0 mg/kg in rats (Kiyatkin & Sharma, 
2009). Although not significant, this suggests that it takes different amounts of 
drug for MA to be considered a lethal dose in the two species. Therefore, it is 
important to consider that my studies were done in rats whereas their studies 
were done in mice, and the differences in the doses of drug could have led to 
differences in cognitive impairments. 
 It is important to explore the different possibilities that are contributing to 
the impairments seen in novelty detection after one day of abstinence, but not 
after 30 days of abstinence. As mentioned above, lesioning the HC bilaterally 
impairs novelty detection (Broadbent et al., 2010). Damage to the HC has also 
been associated with impaired recognition memory in humans (McKee & Squire, 
1993) and in monkeys (Pascalis & Bachevalier, 1999). These studies suggest 
that since damage to the HC produces deficits in recognition memory, it is 
possible that there may be initial alterations in the HC preventing the expression 
of NOR, but these alterations do not persist for up to 30 days after abstinence. 
This suggests that HC functioning was altered shortly after chronic intermittent 
injections, but functioning recovered after prolonged abstinence. Recovery of 
recognition memory after 30 days of abstinence may be due to the fact that the 
    
 
54 
HC is extremely prone to neuroplasticity (McEwen, 1990). Since the HC is 
undergoing neuroplasticity quicker than other regions, it is possible that MA 
initially causes impairments in HC functioning, but with the process of synaptic 
plasticity, begins to recover after some amount of time. Another possible reason 
for HC-mediated recovery may be due to the recent findings that the dentate 
gyrus, which is a part of the hippocampal formation, is one of two regions in the 
brain that generates new cells (Schmidt-Hieber et al., 2004). It is possible that 
the initial impairments seen in NOR may be due to MA-induced cell death in the 
hippocampus (Deng et al., 2001); however, after prolonged abstinence, the HC 
undergoes neurogenesis, which contributes to a reversal of impairments seen in 
cognition. Furthermore, impairments in NOR could be due to disruptions in DA 
transmission after long-term MA administration. In the study by Kamei et al. 
mentioned above, they observed that antagonizing D1 receptors via peripheral 
injections prevented MA-treated rats from exhibiting impairments in NOR.  
 The DA system is not only involved in TOR as mentioned previously, but 
also involved in novelty detection. However, it is possible that alterations in DA 
are affecting the regions involved in mediating TOR and NOR differently. For 
example, it is possible that alterations in DA transmission in the mesolimbic 
pathway or in the mesocortical pathway differentially contribute to the 
impairments seen in NOR and TOR, respectively. The mesolimbic pathway, 
which sends neuronal projections primarily containing DA from the VTA to the 
limbic system, could be altered acutely after prolonged MA administration, but 
may be recovering after extended abstinence. Since the HC is a part of the limbic 
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system, MA could be causing changes in DA transmission in the areas receiving 
DA, such as the limbic system (HC) and thereby causing impairments in 
recognition memory. Moreover, the mesocortical pathway, which sends DA 
projections from the VTA to cortical areas (such as the PFC), may be involved in 
TOR. MA could be altering DA transmission in this pathway and causing long-
term alterations in the PFC, thereby contributing to the persistent impairments 
observed in TOR after chronic MA sensitization. However, these are all 
speculations since I have only examined behavioral differences in TOR and NOR 
after MA administration. 
 It is important to mention that the impairments seen in my studies were 
due to the sensitizing regimen and not due to the acute effects of MA. As 
mentioned previously in the TOR section, MA-treated rats showed no 
impairments in TOR after a single injection of 5.0 mg/kg of MA. Similarly, they did 
not show impairments in NOR after an injection 5.0 mg/kg of MA. In both cases, 
saline-treated rats also had no impairments in novelty detection. These findings 
suggest that impairments seen in NOR after sensitization were likely due to the 
long-term neuronal changes induced by chronic MA administration. These results 
also suggest that one injection did not induce alterations to the functioning of the 
HC, as well as changes synaptic plasticity or in neuronal firing rate, therefore not 
contributing to impairments in recognition memory. Lastly, it is possible that the 
DA system was not significantly altered after only one injection of MA. Perhaps at 
this point, the mesolimbic projection neurons were still intact and sending 
dopaminergic projections to the HC.   
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 These animal findings of recovery in recognition memory after MA 
administration are interesting because Salo et al. (2009 & 2011) has recently 
observed that humans who chronically abuse MA have impairments in cognition 
which may recover after prolonged abstinence. The results in NOR recovery after 
prolonged abstinence is important since these studies have found that there may 
be initial deficits in cognition, but after prolonged abstinence, these deficits may 
start to recover. Since I also observed recovery in specific cognitive functions 
after extended abstinence, this animal model provides a good tool to start 
examining the neurobiological and neurochemical differences that contribute to 
the impairments that persist or recover after MA administration. Also, this animal 
model could be used for pharmacological manipulations to better understand the 
underlying neuronal mechanisms contributing to these cognitive impairments and 
the alterations in these mechanisms that eventually lead to a recovery in 
cognition. 
 Collectively, these studies suggest that the functioning of the PFC is 
altered after short-term and long-term abstinence, and therefore, causes 
chronically sensitized MA rats to be impaired in temporal memory. Additionally, 
HC functioning is altered after short-term abstinence but seems to recover after 
long-term abstinence, suggesting recovery of HC functioning. This further 
suggests that novelty detection is impaired initially, but recovers after prolonged 
abstinence. These findings with recognition memory are similar to the human 
findings of Salo et al. who shows that there may be recovery in cognitive function 
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after prolonged abstinence. This sensitization model provides a good tool to 
examine the underlying mechanisms involved in the recovery process.  
 
 
Future Studies 
 
 
 Future studies will assess the electrophysiological underpinnings of mPFC 
and HC functioning while undergoing TOR and NOR in awake, behaving rodents 
that self-administer MA to get a better understanding of the extent to which these 
regions are causing impairments in cognition after one day and prolonged 
abstinence. Additionally, synchrony and firing patterns would be assessed to get 
a better understanding of communication between these two regions to see if 
they are communally affecting cognition. Lastly, D-Govadine, which is shown to 
be a cognitive enhancer by increasing DA efflux (Lapish et al. in preparation), 
would be administered after inducing MA impairments in temporal and 
recognition memory to examine if this stereoisomer would remediate the 
impairments in cognition caused by MA. This would provide a treatment strategy 
for those affected with long-term MA addiction and will hopefully decrease or 
alleviate the cognitive deficits associated with chronic MA use. 
 
 
Summary 
 
 
 In conclusion, these findings demonstrate that high, chronic doses of MA 
cause behavioral sensitization and short-term impairments in temporal 
sequencing and novelty detection, which suggests alterations in the mPFC and 
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HC, respectively. Further, the MA-induced mPFC dysfunction is static after 30 
days of abstinence, although HC functioning is remediated with prolonged 
abstinence. This suggests two different mechanisms in which MA affects 
cognitive substrates.  
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A. 1-day Abstinence 
Day 1-7           Day 8-20         Day 28         Day 29       Day 30      Day 31-60    Day 61-62 
  
B. 30-day Abstinence 
Day 1-7          Day 8-20         Day 28       Day 29-58        Day 59  Day 60      Day 61-62 
 
 
C. Single Injection 
Day 1-7            Day 8            Day 9 
 
 
D. Acute Injection 
Day 1-7                Day 8 
  
  
Figure 1: Timeline of Experiments: A timeline of the experiments during 1-day 
abstinence (A), 30-day abstinence (B), single injection (C) and acute injection 
(D). 
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Figure 2: Timeline of Behavioral Sensitization. Animals were injected with either 
5.0 mg/kg of MA or saline every other day for 13 days, for a total of 7 injections 
(Day 1-13, induction phase). 1 week after the induction phase, rats were injected 
again to confirm sensitization (Day 21). 
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Figure 3: Locomotor Activity & Stereotypy: Induction Phase. Locomotor activity 
and stereotypy during the induction phase. (A) Locomotor activity (mean ± SEM) 
post-injection. Initially, MA-treated rats increased locomotor output when  
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Figure 3: continued, compared to saline-treated rats, but after repeated 
administration, MA-treated rats exhibited a decrease in locomotor activity; 
*(Bonferroni post-hoc, p < 0.05), ***(Bonferroni post-hoc, p < 0.005), significantly 
different than saline-treated rats. (B) Stereotypy rating (mean ± SEM) post-
injection during the induction phase. MA-treated rats increased stereotypy 
throughout the induction phase when compared to saline-treated rats; 
**(Bonferroni post-hoc, p < 0.005), significantly different from MA-treated rats on 
Day 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
          
 
88
  A.         B.  
0 10 20 30 40 50 60
0
2
4
6
8
10
MA
Saline
*
Minutes
Lo
co
mo
to
r  
Ac
tiv
ity
 (m
et
er
s)
0 10 20 30 40 50 60
0
2
4
6
8
10
***
Saline
MA
Minutes
Lo
co
mo
to
r  
Ac
tiv
ity
 (m
et
er
s)
 
  
             C.  
0 10 20 30 40 50 60
0
2
4
6
8
10
MA Day 1
MA Day 21
** ** ** ***
***
Minutes
Lo
co
mo
to
r  
Ac
tiv
ity
 (m
et
er
s)
 
 
Figure 4: Locomotor Activity 5-Minute Bins: Day 1 Vs. Day 21. Locomotor activity 
in 5-minute bins during the induction phase. (A) Locomotor activity (mean ± 
SEM) post-injection on Day 1. As the induction phase progressed, MA-treated 
rats had an increase in locomotor activity; *(Bonferroni post-hoc, p < 0.05), 
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Figure 4: continued, significantly different than saline-treated rats. (B) Locomotor 
activity (mean ± SEM) post-injection on Day 21. Soon after the injection, there 
were no differences in locomotor activity between MA-treated and saline-treated 
rats; ***(Bonferroni post-hoc, p < 0.001), significantly different than saline-treated 
rats. (C) Locomotor activity (mean ± SEM) post-injection on Day 1 vs. Day 21 in 
the MA-treated rats. On Day 1 of the injection, MA-treated rats had an increase in 
locomotor activity, with a significant decrease in locomotor activity on Day 21 as 
the induction phase progressed; **(Bonferroni post-hoc, p < 0.01), ***(Bonferroni 
post-hoc, p < 0.001), significantly different than locomotor activity scores on Day 
21. 
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                              Saline Day 1          Saline Day 21 
      
 
                MA Day 1                        MA Day 21 
          
 
Figure 5: Locomotor Activity Animal Path: Day 1 Vs. Day 21. Animal paths post- 
injection of saline-treated (top) and MA-treated (bottom) rats on Day 1 (left) and 
Day 21 (right) of the induction phase. 
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Figure 6: Locomotor Activity and Stereotypy: MA Challenge. Locomotor activity 
(mean ± SEM) and stereotypy (mean ± SEM) during MA challenge. (A) All rats 
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Figure 6: continued, that received MA (0.5 mg/kg) showed increased locomotor 
activity compared to the rats that received saline; *(Bonferroni post-hoc, p < 
0.05), ***(Bonferroni post-hoc, p < 0.0005), significantly different than saline 
injection. (B) Chronic saline-treated rats that received MA (5.0 mg/kg) showed 
increased locomotor activity; **(Bonferroni post-hoc, p < 0.005), significantly 
different from all other groups. (C) There were no significant differences in 
stereotypy scores between either of the groups or treatments after a 0.5 mg/kg 
MA or saline injection. (D) MA injections (5.0 mg/kg) evoked stereotypy in both 
chronic saline-treated and chronic MA-treated rats when compared to rats that 
received a saline injection, but was more robust in chronic MA-treated rats; 
#(Tukey’s   post-hoc, p < 0.05), chronically treated MA rats injected with MA 
significantly greater than chronically treated saline rats injected with MA; 
**(Bonferroni post-hoc, p < 0.005), MA injection significantly greater than saline 
injections across treatments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          
 
93
  A.       B.  
Saline MA
0
50
100
150
So
ci
al
 in
te
ra
ct
io
n 
tim
e 
(s
ec
)
Saline MA
0
50
100
150
So
cia
l in
te
ra
ct
io
n 
tim
e (
se
c)
 
 
 
            C.  
Saline MA
0
50
100
150
***
So
cia
l in
te
ra
ct
io
n 
tim
e (
se
c)
 
 
 
Figure 7: Social Interaction. Social interaction time (mean ± SEM) during the SI 
task. There were no significant differences in social interaction time between the 
chronic saline-treated and chronic MA-treated rats during the SI task 1 day (A) or 
30 days (B) following abstinence. (C) Rats injected with 5.0 mg/kg of MA  
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Figure 7: continued, interacted significantly less 30 minutes after the injection 
compared to the rats that received saline; ***(unpaired t-test, p < 0.0005), 
significantly greater than saline-treated rats. 
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A.              B. 
 
 
Figure 8: Temporal Order Recognition: 1-Day & 30-Day Abstinence. TOR after 1-
day or 30-days of abstinence. (A) Total time interacted (mean ± SEM) 1 day 
following the last day of the induction phase. Saline-treated rats, but not MA-
treated rats, exhibited TOR after 1-day of abstinence(B) Total time interacted 
(mean ± SEM) 30 days following the last day of the induction phase. Saline-
treated rats, but not MA-treated rats, exhibited TOR after 30 days of abstinence; 
**(paired t-test, p < 0.005).  
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Figure 9: Novel Object Recognition: 1-Day & 30-Day Abstinence. NOR after 1-
day or 30-days of abstinence. (A) Total time interacted (mean ± SEM) 1 day 
following the last day of the induction phase. Saline-treated rats, but not MA-
treated rats NOR after 1-day of abstinence(B) Total time interacted (mean ± 
SEM) 30 days following the last day of the induction phase. Both saline-treated 
and MA-treated rats exhibited NOR after 30 days of abstinence; *(paired t-test, p 
< 0.05), *(paired t-test, p < 0.005) 
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Figure 10: Single Injection. TOR and NOR after a single injection. Total time 
interacted (mean ± SEM) 1 day following a single injection of MA or saline. Both 
treatment groups exhibited TOR (A) and NOR (B) after a single injection of MA or 
saline; *(paired t-test, p < 0.05).  
 
